TrialCompass™ TCL
Back to results
Not yet recruitingPriority 4 · Lower priorityNCT07339527

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is testing Zeprumetostat, Golidocitinib, and other medications for people whose anaplastic large cell lymphoma (ALCL) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Zeprumetostat (DRUG): 350mg, po, bid | Golidocitinib (DRUG): Cohort 1: Golidocitinib: 150mg, po, qd | Chidamide (DRUG): Cohort 2: Chidamide: 20mg, po, biw

Drugs / treatments
Zeprumetostat, Golidocitinib, Chidamide
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

NCT07339527

Phase: Phase 1, Phase 2 | Status: Not yet recruiting | Priority: Lower

Plain-language summary

This Phase 1, Phase 2 trial is testing Zeprumetostat, Golidocitinib, and other medications for people whose anaplastic large cell lymphoma (ALCL) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Zeprumetostat (DRUG): 350mg, po, bid | Golidocitinib (DRUG): Cohort 1: Golidocitinib: 150mg, po, qd | Chidamide (DRUG): Cohort 2: Chidamide: 20mg, po, biw

Drugs / treatments: Zeprumetostat, Golidocitinib, Chidamide

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 60 patients

Primary endpoint: DLT for Phase 1b; Overall response rate(ORR) for Phase 2; RP2D for phase Ib

Ages: 18 Years to —

Start date: 2026-01-01 | Est. completion: 2030-01-01

Locations

0 US sites · 0 total

Contact

Qingqing Cai, MD. PhD. | caiqq@sysucc.org.cn | +862087342823

Sponsor: Sun Yat-sen University (OTHER)

Tags

ALCL · ENKTL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07339527

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.